(Q87179773)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822829%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

Epithelial-mesenchymal transition: a new target in anticancer drug discovery (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822829%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822829%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

Giorgio Stassi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822829%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Ruggero De Maria

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822829%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

publication date

29 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822829%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

6 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822829%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822829%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822829%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

311-325

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26822829%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrd.2015.13

6 March 2020

exact match

0 references

cites work

Epithelial-mesenchymal transitions in development and disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

EMT: when epithelial cells decide to become mesenchymal-like cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Snail blocks the cell cycle and confers resistance to cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roads

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Notch signaling mediates hypoxia-induced tumor cell migration and invasion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Acidic pH enhances the invasive behavior of human melanoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Regulation of Epithelial-Mesenchymal Transition by Transmission of Mechanical Stress through Epithelial Tissues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

A CXCL1 paracrine network links cancer chemoresistance and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Hypoxia-induced genetic instability--a calculated mechanism underlying tumor progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Selective targeting of radiation-resistant tumor-initiating cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

The epigenetics of epithelial-mesenchymal plasticity in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Secreted and transmembrane wnt inhibitors and activators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

The transcription factor GATA6 enables self-renewal of colon adenoma stem cells by repressing BMP gene expression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

NF-κB regulates mesenchymal transition for the induction of non-small cell lung cancer initiating cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Wnt/β-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1α signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Regulatory networks defining EMT during cancer initiation and progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

The epithelial-mesenchymal transition generates cells with properties of stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

miR-200b inhibits prostate cancer EMT, growth and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

MicroRNA-21: a novel therapeutic target in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

GPI/AMF inhibition blocks the development of the metastatic phenotype of mature multi-cellular tumor spheroids.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Screening therapeutic EMT blocking agents in a three-dimensional microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Mesenchymal-mode migration assay and antimetastatic drug screening with high-throughput microfluidic channel networks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

A synthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

A systems view of epithelial-mesenchymal transition signaling states

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Hypoxia and hypoxia-inducible factors: master regulators of metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Hypoxia-inducible factor 1alpha mediates anoikis resistance via suppression of alpha5 integrin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

RETRACTED: Lysyl oxidase is essential for hypoxia-induced metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Lysyl oxidase contributes to mechanotransduction-mediated regulation of transforming growth factor-β signaling in breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Inactivation of lysyl oxidase by β-aminopropionitrile inhibits hypoxia-induced invasion and migration of cervical cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

The rationale for targeting the LOX family in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Hypoxia and the extracellular matrix: drivers of tumour metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Targeting the c-Met/FZD8 signaling axis eliminates patient-derived cancer stem-like cells in head and neck squamous carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

PRRX1 promotes epithelial-mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Regulation of EMT by Notch signaling pathway in tumor progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Epithelial-mesenchymal transition in breast cancer lines is mediated through PDGF-D released by tissue-resident stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Autocrine PDGFR signaling promotes mammary cancer metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Endothelial cell-secreted EGF induces epithelial to mesenchymal transition and endows head and neck cancer cells with stem-like phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

TGF-β1 and FGF2 stimulate the epithelial-mesenchymal transition of HERS cells through a MEK-dependent mechanism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Role of β5-integrin in epithelial-mesenchymal transition in response to TGF-β.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Targeting the HGF/c-MET pathway in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Notch signaling: switching an oncogene to a tumor suppressor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

A new tumor suppressor role for the Notch pathway in bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

WNT signalling pathways as therapeutic targets in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Glycogen synthase kinase 3 inhibitors induce the canonical WNT/β-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Matrix rigidity regulates a switch between TGF-β1-induced apoptosis and epithelial-mesenchymal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Induction of heart valve lesions by small-molecule ALK5 inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

STATs in cancer inflammation and immunity: a leading role for STAT3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

FAK in cancer: mechanistic findings and clinical applications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Function of focal adhesion kinase scaffolding to mediate endophilin A2 phosphorylation promotes epithelial-mesenchymal transition and mammary cancer stem cell activities in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Caveolin-1 up-regulation during epithelial to mesenchymal transition is mediated by focal adhesion kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Src kinases as therapeutic targets for cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Current status of SRC inhibitors in solid tumor malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Ran GTPase induces EMT and enhances invasion in non-small cell lung cancer cells through activation of PI3K-AKT pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial-mesenchymal transition induced by hypoxia and TGF-β1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Effect of AKT inhibition on epithelial-mesenchymal transition and ZEB1-potentiated radiotherapy in nasopharyngeal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Colorectal cancer stem cells: from the crypt to the clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

First Axl inhibitor enters clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Attenuation of reactive oxygen species by antioxidants suppresses hypoxia-induced epithelial-mesenchymal transition and metastasis of pancreatic cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Activation of NADPH oxidase subunit NCF4 induces ROS-mediated EMT signaling in HeLa cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Metformin: multi-faceted protection against cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

7,12-dimethylbenz(a)anthracene treatment of a c-rel mouse mammary tumor cell line induces epithelial to mesenchymal transition via activation of nuclear factor-kappaB.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Nuclear factor-κB-dependent epithelial to mesenchymal transition induced by HIF-1α activation in pancreatic cancer cells under hypoxic conditions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Toll-like receptor 4 (TLR4) is essential for Hsp70-like protein 1 (HSP70L1) to activate dendritic cells and induce Th1 response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Systems analysis reveals a transcriptional reversal of the mesenchymal phenotype induced by SNAIL-inhibitor GN-25.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Suppression of cancer relapse and metastasis by inhibiting cancer stemness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

To "grow" or "go": TMEM16A expression as a switch between tumor growth and metastasis in SCCHN.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Cellular heterogeneity profiling by hyaluronan probes reveals an invasive but slow-growing breast tumor subset.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Stromal fibroblasts in cancer initiation and progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Accessories to the crime: functions of cells recruited to the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma and pancreatic tumor cell lines: the role of neutrophils and neutrophil-derived elastase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Adipocyte-derived endotrophin promotes malignant tumor progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Cancer stem-like cells derived from chemoresistant tumors have a unique capacity to prime tumorigenic myeloid cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

MicroRNAs and other non-coding RNAs as targets for anticancer drug development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.13

Src signaling in cancer invasion

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26822829

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26822829

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26822829